By Fineline Cube 
China-based BGI Genomics Co., Ltd (SHE: 300676) announced the launch of its mini breast cancer 76-gene detection system. This innovative solution offers personalized treatment guidance for breast cancer patients through a single test that covers genetic risk assessment, targeted therapy, immunotherapy, and chemotherapy drug recommendations.
Comprehensive Biomarker Analysis
The system simultaneously analyzes critical biomarkers including *AKT, PIK3CA, PTEN, ESR1, BRCA1/2, HER2, and NTRK. It evaluates targeted drug efficacy, assesses endocrine therapy resistance risk, determines PARP inhibitor suitability, and identifies drug resistance mechanisms. The product supports both tumor tissue and ctDNA testing to enhance accuracy and broaden clinical applicability.
Clinical and Hereditary Applications
Beyond providing clinical therapy references, the system aids in the screening of BRCA and other high-risk hereditary genes, enabling family risk assessment. As part of BGI’s solid tumor detection series, this advancement aims to enhance precision oncology for breast cancer and nine other prevalent cancers.-Fineline Info & Tech